Next-generation sequencing on fine needle aspirates in neck recurrence of thyroid cancers
Authors' conclusion
NGS performed on fine needle aspirates of neck lymph node metastases enabled the identification of an oncogenic driver alteration in 53% of the cases in our series of advanced thyroid cancer patients and could significantly alter patient management.
Study context
- Population
- Patients with cervical thyroid cancer recurrences who had DNA and/or RNA-based Next Generation Sequencing (NGS) on ultrasound (US)-guided fine needle aspirates, July 2019 to September 202233 patients
- Participants
- 34 vs 32
- Exposure
- DNA-based NGS vs RNA-based NGS
- DNA-based NGSn = 34
- RNA-based NGSn = 32
- Outcome
- Performance of targeted DNA and RNA-based NGS on fine needle aspirates from thyroid cancer cervical recurrences
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Conclusive/interpretable NGS on US-guided fine needle aspirates of cervical recurrences
| Group | Value | Oncogenic driver identified | Most common mutation BRAF c.1799T>A |
|---|---|---|---|
| DNA-based NGS | 79% | 18 patients (53%) | n = 13 |
| RNA-based NGS | 81% |
Value
DNA-based NGS79%
RNA-based NGS81%
Oncogenic driver identified
DNA-based NGS18 patients (53%)
RNA-based NGS— not stated in the abstract
Most common mutation BRAF c.1799T>A
DNA-based NGSn = 13
RNA-based NGS— not stated in the abstract
Observational data: associations, not effects.
Further findings
Impact on management
- BRAFV600E identification decisive; prescribed dabrafenib and trametinib
- 1 patient
Original publication
Next-generation sequencing on fine needle aspirates in neck recurrence of thyroid cancers. Eur Thyroid J. Published 19 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →